Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. AAPL
6. RTB
7. ONON
8. AZN
9. SPCX
10. TRMD

Go back to Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs
(NASDAQ: AUPH) Delayed: 16.90 -0.06 (0.35%)
Previous Close $16.96    52 Week High $5.69 
Open $16.93    52 Week Low $1.42 
Day High $17.03    P/E N/A 
Day Low $16.80    EPS $0.00 
Volume 1,198,255